查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1434246

抗病毒藥物市場：按藥物、治療方法和分銷分類 - 全球預測 2023-2030

Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2022年抗病毒藥物市場規模為695.4億美元，2023年達755.3億美元，預計2030年將達1,318.2億美元，複合年成長率為8.32%。

全球抗病毒藥物市場

主要市場統計
基準年[2022] 695.4億美元
預計年份 [2023] 755.3億美元
預測年份 [2030] 1318.2億美元
複合年成長率（%） 8.32%
抗病毒藥物-IMG1

抗病毒藥物是專門設計用於透過針對病毒病原體並抑制其複製來減輕病毒性疾病的症狀和傳播的治療方法。抗病毒藥物用於各種醫療機構，從醫院到專科診所再到居家醫療。它們用於治療多種病毒感染疾病，包括流感、肝炎、人類免疫力缺乏病毒 (HIV)、單純皰疹病毒 (HSV) 以及最近的 SARS-CoV-2。由於世界各地各種慢性和病毒性疾病的盛行率不斷增加，對抗病毒藥物的需求正在擴大。藥物研發活動的成長以及醫療保健成本的上升正在推動抗病毒藥物市場的成長。與抗病毒藥物相關的副作用增加了藥物開發的成本並阻礙了抗病毒藥物的成長。市場供應商擴大抗病毒藥物研發活動預計將創造市場成長機會。

區域洞察

在美洲，由於大型製藥公司的存在、先進的醫療基礎設施以及病毒感染疾病的流行，抗病毒藥物市場高度發展。公共和私營部門的大量投資推動了對創新治療方法和研發 (R&D) 的關注。歐盟 (EU) 國家共同代表一個重要的市場，並由歐洲藥品管理局 (EMA) 進行全面監管。高醫療保健標準和相對富裕的人口創造了消費者對最新治療方案的強烈需求。許多歐盟國家普及全民健保，這意味著購買行為在很大程度上取決於監管部門的核准和國家醫療保健政策。中東和非洲 (MEA) 擁有多元化的市場，獲得醫療保健的程度也各不相同。中東富裕國家擁有投資現代治療方法的財政資源，但許多非洲國家在取得方面面臨重大障礙。亞太地區正在迅速擴大其在抗病毒藥物市場的影響力，其特點是對藥物研發的投資增加以及需要醫療照護的人口基數不斷成長。該地區本地製造業的不斷增加和政府為改善醫療保健而採取的舉措正在推動亞太地區的市場成長。

FPNV定位矩陣

FPNV定位矩陣對於評估抗病毒藥物至關重要。我們檢視與商務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種詳細的分析使用戶能夠根據自己的要求做出明智的決策。根據評級，供應商被分為四個不同的象限，代表不同的成功程度：前沿 (F)、探路者 (P)、利基 (N) 或重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗病毒藥物供應商的現狀進行深入而詳細的檢查。仔細比較和分析供應商在整體收益、客戶群和其他關鍵指標方面的貢獻，幫助企業更好地了解其績效以及在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年期間觀察到的累積、分散優勢和合併特徵等因素。這種擴展的詳細程度使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告在以下方面提供了寶貴的見解：

1-市場滲透率：顯示主要企業提供的有關市場的全面資訊。

2- 市場發現：深入研究盈利的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多樣性：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4- 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管核准、專利形勢和製造能力進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的智慧見解。

該報告解決了以下關鍵問題：

1-抗病毒藥物市場的市場規模和預測是多少？

2-在抗病毒藥物市場的預測期內，我們應該考慮投資哪些產品、細分市場、應用和領域？

3-抗病毒藥物市場的技術趨勢和法律規範是什麼？

4-抗病毒藥物主要供應商的市場佔有率是多少？

5-抗病毒藥物進入領域合適的模式和策略性舉措是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 包括愛滋病毒和肝炎在內的病毒性疾病盛行率上升
      • 抗病毒藥物在兒童及呼吸系統疾病的應用
      • 私人公司加大力度遏止病毒感染疾病
    • 抑制因素
      • 抗病毒藥物治療的費用相對較高
    • 機會
      • 加速藥物發現的分子生物學進展
      • 改進病毒感染疾病的測試和分析
    • 任務
      • 抗病毒藥物的副作用
  • 市場區隔分析
    • 藥物：增加使用抗流感病毒藥物來治療和預防流感
    • 治療方法：使用 DNA聚合酵素抑制劑來控制 HSV 和 VZV 的趨勢不斷成長
    • 分銷：由於數位轉型力度加大，線上藥局的採用率增加
  • 市場趨勢分析
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 抗病毒藥物市場（按藥物）

  • 肝炎抗病毒藥
  • 皰疹抗病毒藥物
  • 愛滋病毒抗病毒藥物
  • 抗流感病毒藥物

第7章 抗病毒藥物市場：依治療方法

  • DNA聚合酵素抑制劑
    • 非核苷類
    • 嘌呤核苷類似物
    • 嘧啶核苷類似物
  • 神經氨酸酶抑制劑
  • 蛋白酶抑制劑
  • 逆轉錄酶抑制劑
    • 非核苷類RTI
    • 核苷RTI
    • 核苷酸逆轉錄酶

第8章 抗病毒藥物市場：依分佈

  • 醫院藥房
  • 獨立藥房和藥局
  • 網路藥房

第9章美洲抗病毒藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗病毒藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲抗病毒藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析
    • 合約、合作和夥伴關係
    • 新產品發布和功能增強
    • 獎項/獎勵/擴展

第13章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • Alkem Laboratories Limited
    • AstraZeneca PLC
    • Atea Pharmaceuticals, Inc.
    • Aurobindo Pharma Limited
    • Bristol-Myers Squibb Company
    • Cipla Ltd.
    • Cocrystal Pharma, Inc.
    • Daiichi Sankyo Company, Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Hetero Labs Limited
    • Johnson & Johnson Services Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Limited
    • Syngene International Limited
    • Takeda Pharmaceutical Company Limited
    • Themis Medicare Ltd.
    • Venatorx Pharmaceuticals, Inc.
    • Viatris Inc.
    • Zydus Lifesciences Limited
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-037F3DB2592C

[199 Pages Report] The Antiviral Therapeutics Market size was estimated at USD 69.54 billion in 2022 and expected to reach USD 75.53 billion in 2023, at a CAGR 8.32% to reach USD 131.82 billion by 2030.

Global Antiviral Therapeutics Market

KEY MARKET STATISTICS
Base Year [2022] USD 69.54 billion
Estimated Year [2023] USD 75.53 billion
Forecast Year [2030] USD 131.82 billion
CAGR (%) 8.32%
Antiviral Therapeutics Market - IMG1

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics. Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

Regional Insights

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options. The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Limited, AstraZeneca PLC, Atea Pharmaceuticals, Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Ltd., Cocrystal Pharma, Inc., Daiichi Sankyo Company, Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Labs Limited, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Syngene International Limited, Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Hepatitis Antiviral Drug
    • Herpes Antiviral Drug
    • HIV Antiviral Drug
    • Influenza Antiviral Drug
  • Therapy
    • DNA Polymerase Inhibitors
      • Non-nucleosides
      • Purine Nucleoside Analogues
      • Pyrimidine Nucleoside Analogues
    • Neuraminidase Inhibitors
    • Protease Inhibitors
    • Reverse Transcriptase Inhibitors
      • Nonnucleoside RTIs
      • Nucleoside RTIs
      • Nucleotide RTIs
  • Distribution
    • Hospital Pharmacy
    • Independent Pharmacy & Drug Store
    • Online Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antiviral Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antiviral Therapeutics Market?

4. What is the market share of the leading vendors in the Antiviral Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antiviral Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antiviral Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Viral Diseases Including HIV and Hepatitis
      • 5.1.1.2. Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
      • 5.1.1.3. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively High Cost Associated with Antiviral Drug Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Molecular Biology Promoting Drug Development
      • 5.1.3.2. Improved Testing and Analysis of Viral Infections
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse Effects of Antiviral Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
    • 5.2.2. Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
    • 5.2.3. Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of COVID-19
  • 5.5. Cumulative Impact of Russia-Ukraine Conflict
  • 5.6. Cumulative Impact of High Inflation
  • 5.7. Porter's Five Forces Analysis
    • 5.7.1. Threat of New Entrants
    • 5.7.2. Threat of Substitutes
    • 5.7.3. Bargaining Power of Customers
    • 5.7.4. Bargaining Power of Suppliers
    • 5.7.5. Industry Rivalry
  • 5.8. Value Chain & Critical Path Analysis
  • 5.9. Regulatory Framework
  • 5.10. Client Customization

6. Antiviral Therapeutics Market, by Drug

  • 6.1. Introduction
  • 6.2. Hepatitis Antiviral Drug
  • 6.3. Herpes Antiviral Drug
  • 6.4. HIV Antiviral Drug
  • 6.5. Influenza Antiviral Drug

7. Antiviral Therapeutics Market, by Therapy

  • 7.1. Introduction
  • 7.2. DNA Polymerase Inhibitors
    • 7.3.1. Non-nucleosides
    • 7.3.2. Purine Nucleoside Analogues
    • 7.3.3. Pyrimidine Nucleoside Analogues
  • 7.3. Neuraminidase Inhibitors
  • 7.4. Protease Inhibitors
  • 7.5. Reverse Transcriptase Inhibitors
    • 7.6.1. Nonnucleoside RTIs
    • 7.6.2. Nucleoside RTIs
    • 7.6.3. Nucleotide RTIs

8. Antiviral Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Independent Pharmacy & Drug Store
  • 8.4. Online Pharmacy

9. Americas Antiviral Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antiviral Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Agreement, Collaboration, & Partnership
      • 12.3.1.1. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
    • 12.3.2. New Product Launch & Enhancement
      • 12.3.2.1. Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
    • 12.3.3. Award, Recognition, & Expansion
      • 12.3.3.1. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Alkem Laboratories Limited
    • 13.1.4. AstraZeneca PLC
    • 13.1.5. Atea Pharmaceuticals, Inc.
    • 13.1.6. Aurobindo Pharma Limited
    • 13.1.7. Bristol-Myers Squibb Company
    • 13.1.8. Cipla Ltd.
    • 13.1.9. Cocrystal Pharma, Inc.
    • 13.1.10. Daiichi Sankyo Company, Ltd.
    • 13.1.11. Dr. Reddy's Laboratories Ltd.
    • 13.1.12. Eli Lilly and Company
    • 13.1.13. F. Hoffmann-La Roche Ltd
    • 13.1.14. Gilead Sciences, Inc.
    • 13.1.15. GlaxoSmithKline PLC
    • 13.1.16. Hetero Labs Limited
    • 13.1.17. Johnson & Johnson Services Inc.
    • 13.1.18. Merck & Co., Inc.
    • 13.1.19. Novartis AG
    • 13.1.20. Pfizer Inc.
    • 13.1.21. Sanofi S.A.
    • 13.1.22. Sun Pharmaceutical Industries Limited
    • 13.1.23. Syngene International Limited
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Themis Medicare Ltd.
    • 13.1.26. Venatorx Pharmaceuticals, Inc.
    • 13.1.27. Viatris Inc.
    • 13.1.28. Zydus Lifesciences Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIVIRAL THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIVIRAL THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
  • FIGURE 8. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
  • FIGURE 10. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 12. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 22. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 237. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 238. ANTIVIRAL THERAPEUTICS MARKET LICENSE & PRICING